Side-by-side breakdowns for researchers deciding between two compounds.
Tirzepatide targets two receptors (GIP/GLP-1) and has the longer clinical track record. Retatrutide adds a third (glucagon) and produced larger mean weight change in its own phase 2 trial, but has less real-world data behind it. Neither trial compared the two head-to-head.
Semax is more often studied for focus and cognitive performance, while Selank is more often studied for stress response and anxiolytic-adjacent pathways. They're frequently paired in cognition-focused protocols.
